Could a Sugar-Blocking pill boost immunotherapy for tough cancers?
NCT ID NCT05913388
First seen Apr 23, 2026 · Last updated Jun 19, 2026 · Updated 12 times
Summary
This phase 2 trial tests whether adding an experimental drug called GB1211 to the immunotherapy Keytruda works better than Keytruda alone for people with advanced melanoma or head & neck cancer. GB1211 blocks a protein called galectin-3, which may help tumors hide from the immune system. About 92 participants will receive either the combo or a placebo plus Keytruda, and researchers will measure how many tumors shrink.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Providence Portland Medical Center
RECRUITINGPortland, Oregon, 97213, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GB1211 (a galectin-3 inhibitor) and pembrolizumab (Keytruda)
What this could lead to
If successful, this combination could improve tumor shrinkage rates in advanced melanoma and head & neck cancers compared to standard immunotherapy alone.
What could go wrong
This is a mid-stage trial with only 92 participants, so results may not apply to all patients. Adding GB1211 could also increase side effects without clear benefit.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.